Abstract
Recent studies suggest that sickle cell disease (SCD) is a hypercoagulable state contributing to vaso-occlusive events in the microcirculation, resulting in acute and chronic sickle cell-related organ damage. In this article, we review the existing evidence for contribution of hemostatic system perturbation to SCD pathophysiology. We also review the data showing increased risk of thromboembolic events, particularly newer information on the incidence of venous thromboembolism. Finally, the potential role of platelet inhibitors and anticoagulants in SCD is briefly reviewed.
Original language | English (US) |
---|---|
Pages (from-to) | 355-374 |
Number of pages | 20 |
Journal | Hematology/Oncology Clinics of North America |
Volume | 28 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2014 |
Keywords
- Anti-platelets
- Anticoagulants
- Hypercoagulable
- Sickle cell
- Thromboembolism
ASJC Scopus subject areas
- Oncology
- Hematology
- Medicine(all)